Overcoming Antibiotic-Resistant Infections
Lantibiotics are a class of antibiotic compounds with novel mechanism of action, prized for their ability to overcome antibiotic-resistant infections. With resistant strains on the rise, particularly healthcare-acquired infections (HAI), the need for these potent lantibiotic agents is critical. Oragenics is pursuing the commercial-scale production of a lantibiotic for use as an antimicrobial.
OG716 is a molecule derived from our lantibiotic discovery and characterization platform that has shown positive results in nonclinical testing including efficacy in an animal model for Clostridium difficile infection in enteritis.